Carlyle and SK Capital Partners are buying beleaguered gene therapy biotech Bluebird Bio for about $29 million.

Bluebird bio (BLUE) shares continued their downward descent Monday following news that the company plans to be taken private through a deal valued at up to $96M. Read more here.

Wells Fargo analyst Yanan Zhu lowered the firm’s price target on Bluebird Bio (BLUE) to $5 from $40 and keeps an Equal Weight rating on the ...

12 years after going public, beleaguered gene therapy company bluebird bio will be sold to private equity groups Carlyle and ...

本文来自微信公众号：氨基观察，作者：郑晓，题图来自：Bluebird Bio 创新药企创业，成功是小概率事件，失败、消失是最常见的结局。 过去 20 多年的 biotech ...

蓝鸟因为超前的基因疗法而闻名，率先成功上岸成为先驱，但基因疗法的创新性，导致安全性问题拖延商业化节奏，又因为价格问题导致变现困难…… 一系列因素让蓝鸟持续失血，最终无力回天。

Like other developers of recently approved gene therapies, Bluebird has been slow to generate demand for its products. That reflects challenges in securing reimbursement from payers stemming from ...

Once the hottest property in biotech, gene therapy company bluebird bio has been sold for less than $500 million after a long series of setbacks.

Bluebird Bio announced Friday it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK ...

Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.

A paper published in The Lancet showed that four out of four young children with Leber congenital amaurosis 4 retinal dystrophy due to a genetic deficiency of Aryl-hydrocarbon-interacting protein-like ...

U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling more than 700 points on Friday. The Dow traded down 1.63% to 43,457.49 while the NASDAQ fell 1.63% to 19,637.11.